These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 11280448)
1. Regulation of dosage of conjugated equine estrogen is useful for add-back therapy. Hoshimoto K; Hayashi M; Ohkura T J Med; 2000; 31(3-4):167-75. PubMed ID: 11280448 [TBL] [Abstract][Full Text] [Related]
2. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy. Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826 [TBL] [Abstract][Full Text] [Related]
3. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens. Hansen LM; Batzer FR; Corson SL; Bello S J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500 [TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. Akira S; Mine K; Kuwabara Y; Takeshita T Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964 [TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890 [TBL] [Abstract][Full Text] [Related]
7. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Lethaby AE; Vollenhoven BJ Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660 [TBL] [Abstract][Full Text] [Related]
8. [Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri]. Yoshioka N Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1255-60. PubMed ID: 8543851 [TBL] [Abstract][Full Text] [Related]
9. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331 [TBL] [Abstract][Full Text] [Related]
10. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist. Wen L; Tseng JY; Wang PH Taiwan J Obstet Gynecol; 2006 Jun; 45(2):173-5. PubMed ID: 17197363 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352 [TBL] [Abstract][Full Text] [Related]
12. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas. Saltiel E Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243 [TBL] [Abstract][Full Text] [Related]
13. GnRHa for adhesion formation after uterine serosal injury in an euestrogenic milieu. Ergeneli MH; Kuscu E; Zeyneloglu HB; Haberal A; Erdogan M J Reprod Med; 2000 Jan; 45(1):35-8. PubMed ID: 10664945 [TBL] [Abstract][Full Text] [Related]
14. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Cramer SF Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847 [No Abstract] [Full Text] [Related]
15. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas. Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824 [TBL] [Abstract][Full Text] [Related]
16. Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa. Wang PH; Lee WL; Chao HT; Shu LP; Kao HL; Wu CW; Yuan CC Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):294-9. PubMed ID: 10389284 [TBL] [Abstract][Full Text] [Related]
17. Treatment of perimenopausal women with uterine myoma: successful use of a depot GnRH agonist leading to a natural menopause. Imai A; Sugiyama M; Furui T; Tamaya T J Obstet Gynaecol; 2003 Sep; 23(5):518-20. PubMed ID: 12963511 [TBL] [Abstract][Full Text] [Related]
18. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14). Takahashi K; Kawamura N; Ishiko O; Ogita S Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889 [TBL] [Abstract][Full Text] [Related]
19. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis]. Mettler L Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients. Kopitović V; Bujas M; Fistes Topalski N; Pjević M; Ilić D; Kapamadzija A; Bujas I Med Pregl; 2001; 54(7-8):339-46. PubMed ID: 11905182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]